Novartis to spin off Alcon and launch a $5 billion share buyback

Posted in Biotech

June 29, 2018 • 3 min read

Novartis (NYSE:NVS) is back to focusing on being a drug company as they've decided to spin off Alcon and launch a $5 billion share buyback. This announcement comes after years of speculation that Novartis would part ways with Alcon and investors welcomed the news with the stock up ~4% in early trading....

First medicine made from marijuana receives FDA approval

Posted in Biotech

June 26, 2018 • 4 min read

The FDA announced that they have approved GW Pharmaceuticals’ Epidiolex, a drug designed to treat two rare forms of childhood epilepsy using a cannabis compound called cannabidiol (or CBD). Epidiolex becomes the first prescription pharmaceutical formulation of highly-purified, plant-derived cannabidiol (CBD), a cannabinoid lacking the high associated with marijuana, and the first in a new category of anti-epileptic drugs (AEDs). ...

'Bad Blood' Highlights Greed and Deception at Theranos

Posted in Biotech,

May 24, 2018 • 3 min read

The story of Theranos is so mind-blowing that you are left wondering how it even happened. For example, how did Theranos raise $1.37B in 10 rounds of financing without having a product that did what they promised it would do? ...

Migraine Drug Could Add 10% to Amgen's Revenue

Posted in Biotech

May 21, 2018 • 2 min read

On CNBC's "Power Lunch," a Wall Street analyst stated that Amgen's recently approved migraine drug, Aimovig, could become a $2 billion business in the next five years. That revenue would equate to a 10 percent increase to Amgen's revenue as the drug provides a huge unmet need for adults who deal with migraines. ...